Albino rats |
Both renal I/R (1 h/2 h) |
LA (100 mg/kg, i.p) at 2 days before I/R |
Attenuating histopathological injury via reducing oxidative damage |
[62] |
Wistar albino rats |
Right nephrectomy and left renal I/R (45 min/24 h) |
LA (100 mg/kg, i.p) or saline twice, at 30 min before ischemia |
Inhibiting neutrophil infiltration and inflammation generation, balancing the oxidant-antioxidant status |
[63] |
Sprague-Dawley rats |
Bilateral renal I/R (45 min/24 h) |
Pretreatment with LA (50 mg/kg i.p) for 2 weeks |
Decreasing levels of creatinine and urea together with oxidative stress and inflammation; elevating GSH levels and activities of antioxidant enzymes |
[64] |
Albino Wistar rats |
Right nephrectomy and the left renal I/R (1 h/24 h) |
LA (100 mg/kg, i.p) 30 min before I/R |
Reducing degradation of extracellular matrix and oxidative stress via increasing matrix metalloproteinases-2 and -9 activities and decreasing metalloproteinases-1 and -2 levels |
[65] |
Sprague-Dawley rats |
Bilateral renal I/R (40 min/2 d) |
LA (80 mg/kg i.p) at 48 and 24 h before ischemia and at 6 and 24 h after reperfusion |
Protecting renal function (e.g., aquaporins and sodium transporters) via normalizing activities of local arginine vasopressin/cAMP, nitric oxide/cGMP, and ET systems |
[66] |
Sprague-Dawley rats |
Right nephrectomy and left renal I/R (45 min/24 h) |
LA (10 or 100 mg/kg, i.p) at 24 and 1 h before ischemia |
Attenuating the deterioration of renal function; repressing tubular necrosis, proteinaceous casts in tubuli, and medullary congestion through suppressing ET-1 |
[67] |